Tempest Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $12.6M | $28.5M | $17.5M | $22.5M | $17.2M |
| Operating income | -$26.6M | -$42.0M | -$29.2M | -$34.6M | -$27.0M |
| Interest expense | $207,000 | $1.3M | $1.4M | $1.6M | $1.3M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$26.3M | -$41.8M | -$29.5M | -$35.7M | -$28.3M |
| Balance Sheet | |||||
| Cash and equivalents | $7.7M | $30.3M | $39.2M | $31.2M | $51.8M |
| Current assets | $8.3M | $31.5M | $40.4M | $33.0M | $69.0M |
| Total assets | $16.9M | $41.5M | $51.6M | $46.1M | $73.2M |
| Current liabilities | $3.3M | $14.2M | $9.4M | $7.3M | $20.0M |
| Total liabilities | $10.3M | $22.4M | $24.8M | $28.0M | $37.1M |
| Stockholders' equity | $6.7M | $19.1M | $26.8M | $18.1M | $36.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$26.8M | -$33.0M | -$27.4M | -$31.1M | -$26.0M |
| Depreciation and amortization | $266,000 | $389,000 | $381,000 | $638,000 | $374,000 |
| Stock-based compensation | $3.1M | $5.3M | $2.5M | $1.6M | $1.1M |
| Capital expenditure | $0 | $435,000 | $170,000 | $562,000 | $135,000 |
| Free cash flow | -$26.8M | -$33.5M | -$27.5M | -$31.6M | -$26.1M |
| Dividends paid | — | $0 | $0 | $0 | $0 |
Shares outstanding 14.8M
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.